Moderna Reports Better-Than-Expected Q4 2025 Financials Amid Regulatory Setback
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MRNA?
Source: seekingalpha
- Strong Financial Performance: Moderna reported Q4 2025 revenue of $678 million, exceeding consensus estimates by $54.1 million, despite a ~30% year-over-year decline, indicating the impact of reduced COVID-19 vaccine sales volumes.
- Effective Cost Control: The company saw R&D and SG&A expenses decrease by approximately 31% and 13% year-over-year to about $3.1 billion and $1.0 billion, respectively, while net loss fell ~22% year-over-year to $2.8 billion, demonstrating the effectiveness of its cost reduction initiatives.
- 2026 Growth Target Reaffirmed: Despite facing a regulatory setback with the FDA's refusal to file for its flu vaccine candidate mRNA-1010, Moderna reiterated its expectation of up to 10% revenue growth in 2026, reflecting confidence in its future prospects.
- Stable Cash Flow Position: The company projects year-end cash and investments of $5.5 billion to $6.0 billion for 2026, slightly down from $5.8 billion last year, indicating ongoing efforts in cost control and cash flow management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 40.110
Low
17.00
Averages
29.36
High
63.00
Current: 40.110
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Posts Smaller Loss Than Anticipated, But Stock Declines Following Earnings Report.
Moderna's Quarterly Results: Moderna reported better-than-expected quarterly results, indicating strong performance in its financials.
Stock Performance: Despite the positive earnings report, shares of Moderna slipped on Friday, reflecting market reactions.
See More
MODERNA STOCK PLUMMETS 11.5% FOLLOWING US FDA'S DECISION NOT TO EVALUATE COMPANY'S INFLUENZA VACCINE APPLICATION
Moderna's Stock Reaction: Moderna's shares dropped by 11.5% following the refusal of the U.S. Food and Drug Administration (FDA) to review the company's influenza vaccine application.
FDA's Decision Impact: The FDA's decision not to review the influenza vaccine application has raised concerns about the future of Moderna's vaccine development efforts.
See More
FDA Declines to Review Approval for Moderna's New Flu Vaccine - WSJ
- FDA Refusal: The FDA has declined to consider the approval of Moderna's new flu vaccine.
- Impact on Public Health: This decision may affect the availability of new flu vaccination options for the upcoming flu season.
See More
MODERNA: U.S. FOOD AND DRUG ADMINISTRATION ISSUES REFUSAL-TO-FILE LETTER FOR MRNA-1010 SEASONAL INFLUENZA VACCINE CANDIDATE
Regulatory Update: Moderna has received a refusal letter from the U.S. Food and Drug Administration regarding its investigational seasonal influenza vaccine, mRNA-1010.
Vaccine Details: The vaccine is designed to target multiple strains of the influenza virus, but the FDA's decision indicates concerns that need to be addressed before moving forward.
See More
Moderna Reports Better-Than-Expected Q4 2025 Financials Amid Regulatory Setback
- Strong Financial Performance: Moderna reported Q4 2025 revenue of $678 million, exceeding consensus estimates by $54.1 million, despite a ~30% year-over-year decline, indicating the impact of reduced COVID-19 vaccine sales volumes.
- Effective Cost Control: The company saw R&D and SG&A expenses decrease by approximately 31% and 13% year-over-year to about $3.1 billion and $1.0 billion, respectively, while net loss fell ~22% year-over-year to $2.8 billion, demonstrating the effectiveness of its cost reduction initiatives.
- 2026 Growth Target Reaffirmed: Despite facing a regulatory setback with the FDA's refusal to file for its flu vaccine candidate mRNA-1010, Moderna reiterated its expectation of up to 10% revenue growth in 2026, reflecting confidence in its future prospects.
- Stable Cash Flow Position: The company projects year-end cash and investments of $5.5 billion to $6.0 billion for 2026, slightly down from $5.8 billion last year, indicating ongoing efforts in cost control and cash flow management.
See More
Moderna Q4 2025 Earnings Beat Expectations
- Earnings Highlights: Moderna reported a GAAP EPS of -$2.11, beating expectations by $0.49, demonstrating resilience despite ongoing losses, which may influence investor sentiment positively.
- Revenue Growth: The company achieved Q4 revenue of $678 million, exceeding forecasts by $54.07 million, indicating strong market demand for its products and potentially laying the groundwork for future recovery.
- Market Reaction: Despite the earnings beat, the market remains cautious about Moderna's outlook, particularly following the FDA's halt on the review of mRNA-1010, which could undermine investor confidence.
- Competitive Analysis: In comparison with Novavax, Moderna must continue to showcase its value proposition to navigate the increasingly competitive vaccine market, especially in the post-pandemic landscape.
See More
Moderna Posts Smaller Loss Than Anticipated, But Stock Declines Following Earnings Report.
Moderna's Quarterly Results: Moderna reported better-than-expected quarterly results, indicating strong performance in its financials.
Stock Performance: Despite the positive earnings report, shares of Moderna slipped on Friday, reflecting market reactions.
See More
MODERNA STOCK PLUMMETS 11.5% FOLLOWING US FDA'S DECISION NOT TO EVALUATE COMPANY'S INFLUENZA VACCINE APPLICATION
Moderna's Stock Reaction: Moderna's shares dropped by 11.5% following the refusal of the U.S. Food and Drug Administration (FDA) to review the company's influenza vaccine application.
FDA's Decision Impact: The FDA's decision not to review the influenza vaccine application has raised concerns about the future of Moderna's vaccine development efforts.
See More
FDA Declines to Review Approval for Moderna's New Flu Vaccine - WSJ
- FDA Refusal: The FDA has declined to consider the approval of Moderna's new flu vaccine.
- Impact on Public Health: This decision may affect the availability of new flu vaccination options for the upcoming flu season.
See More
MODERNA: U.S. FOOD AND DRUG ADMINISTRATION ISSUES REFUSAL-TO-FILE LETTER FOR MRNA-1010 SEASONAL INFLUENZA VACCINE CANDIDATE
Regulatory Update: Moderna has received a refusal letter from the U.S. Food and Drug Administration regarding its investigational seasonal influenza vaccine, mRNA-1010.
Vaccine Details: The vaccine is designed to target multiple strains of the influenza virus, but the FDA's decision indicates concerns that need to be addressed before moving forward.
See More
Moderna Reports Better-Than-Expected Q4 2025 Financials Amid Regulatory Setback
- Strong Financial Performance: Moderna reported Q4 2025 revenue of $678 million, exceeding consensus estimates by $54.1 million, despite a ~30% year-over-year decline, indicating the impact of reduced COVID-19 vaccine sales volumes.
- Effective Cost Control: The company saw R&D and SG&A expenses decrease by approximately 31% and 13% year-over-year to about $3.1 billion and $1.0 billion, respectively, while net loss fell ~22% year-over-year to $2.8 billion, demonstrating the effectiveness of its cost reduction initiatives.
- 2026 Growth Target Reaffirmed: Despite facing a regulatory setback with the FDA's refusal to file for its flu vaccine candidate mRNA-1010, Moderna reiterated its expectation of up to 10% revenue growth in 2026, reflecting confidence in its future prospects.
- Stable Cash Flow Position: The company projects year-end cash and investments of $5.5 billion to $6.0 billion for 2026, slightly down from $5.8 billion last year, indicating ongoing efforts in cost control and cash flow management.
See More
Moderna Q4 2025 Earnings Beat Expectations
- Earnings Highlights: Moderna reported a GAAP EPS of -$2.11, beating expectations by $0.49, demonstrating resilience despite ongoing losses, which may influence investor sentiment positively.
- Revenue Growth: The company achieved Q4 revenue of $678 million, exceeding forecasts by $54.07 million, indicating strong market demand for its products and potentially laying the groundwork for future recovery.
- Market Reaction: Despite the earnings beat, the market remains cautious about Moderna's outlook, particularly following the FDA's halt on the review of mRNA-1010, which could undermine investor confidence.
- Competitive Analysis: In comparison with Novavax, Moderna must continue to showcase its value proposition to navigate the increasingly competitive vaccine market, especially in the post-pandemic landscape.
See More
